GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Can Make a Clinic Decline Treatment?

A clinic may decline stem cell treatment because the proposed procedure is too risky for you, the expected benefit is not supported for your condition, your diagnosis falls outside the treatment it can offer, or it cannot provide the necessary consent process and follow-up. Missing medical records can also prevent a decision. Ask whether the answer means more information is needed, treatment should be deferred, or this particular clinic cannot offer the requested treatment.

A refusal from one clinic does not, by itself, establish that every treatment is unsuitable. Equally, a quick acceptance elsewhere does not establish that treatment is safe. The reason for the decision matters more than the word “declined.”

What Can Make a Clinic Decline Treatment?

Missing records can prevent a decision

If the clinic has not explained its decision, ask what it reviewed. Prepare your diagnosis and disease stage, specialist reports, relevant imaging and laboratory results, treatment history, current medicines, allergies, and major health conditions. Ask which documents are missing rather than assuming you have failed a medical eligibility test.

For blood-forming stem cell transplantation in cancer care, the National Cancer Institute describes eligibility factors including cancer type and stage, donor availability, other treatment options, tolerance of high-dose chemotherapy, and other serious health problems Stem cell transplant. These are transplant-specific considerations, not an eligibility checklist that can be transferred unchanged to a private cell infusion.

When discussing the stem cell treatment process in Japan, ask which records need a physician’s review before any treatment decision. An enquiry response or appointment confirmation is not medical clearance.

Health problems may require a pause

If the clinic cites an infection, poorly controlled illness, or concerns about your ability to tolerate the procedure, ask which part of the treatment creates the risk. Cell collection, sedation, surgery, an infusion, and any accompanying medicines need to be considered as parts of the actual plan. Not every cell treatment involves all of these steps.

The U.S. Food and Drug Administration reports serious harms associated with unapproved regenerative products, including blindness, tumor formation, bacterial infections, unwanted inflammatory or immune responses, and contamination during processing Important patient and consumer information about regenerative medicine therapies. This warning explains why product quality and safety review matter; it does not establish a universal exclusion rule for every patient with an infection or chronic illness.

Ask whether a treating specialist’s assessment, updated tests, or a change in the proposed procedure would allow reconsideration. Resolving one concern permits another assessment; it does not guarantee acceptance.

Medicines need an individual review

Give the clinic a complete medicine list, including blood thinners, steroids, immunosuppressants, cancer medicines, and supplements. If a medicine is cited as the reason for a hold, ask the clinic to coordinate with its prescriber. Do not stop or change medicines on your own to qualify.

Cancer history needs a clear explanation

If the refusal mentions cancer, ask whether the concern is active disease, an unexplained finding, interference with current cancer care, or the proposed cell product itself. Bring the relevant oncology records and ask whether an oncologist’s assessment is needed.

Cancer is not a blanket reason to reject all stem cell treatment: blood-forming stem cell transplants are used in the treatment of selected cancers Stem cell transplant. That is different from offering an unproven infusion for another purpose. FDA reports of tumor formation with unapproved regenerative products should not be turned into a claim that every cell therapy causes cancer or that every past cancer diagnosis permanently rules treatment out Important patient and consumer information about regenerative medicine therapies.

Pregnancy, allergies, and procedure requirements

Tell the reviewing physician if you are pregnant, breastfeeding, planning pregnancy, or have had a severe allergic reaction. Ask whether the particular product, collection procedure, accompanying medicines, or clinic protocol excludes treatment in your circumstances. This article does not establish a universal pregnancy or breastfeeding waiting period, and the end of either does not guarantee eligibility.

If an allergy is the concern, ask which ingredient or procedural medicine is involved and whether an alternative can be assessed. For a child or someone with substantial frailty, ask how the team will assess procedural fitness, consent, aftercare, and emergency support. Age alone does not explain what the proposed procedure requires.

Your diagnosis may not fit the treatment

“Stem cell treatment” is not a single interchangeable therapy. A blood-forming stem cell transplant, a cell sheet placed surgically, and a mesenchymal stromal cell infusion involve different products and clinical questions. Japan’s PMDA lists regenerative medical products individually, with product-specific review reports; an approval for one product is not approval for every use of stem cells 0004.

For example, PMDA’s list records Stemirac, an autologous bone marrow-derived mesenchymal stem cell product, under December 2018 conditional and time-limited approval 0004. That historical entry alone cannot establish your current eligibility for treatment of a spinal cord injury. The exact indication, injury details, timing, current product status, and treating center’s requirements need checking.

If a clinic says your diagnosis or stage does not fit, ask it to identify the mismatch. Use the indications and contraindications guide as background for that conversation, not as a substitute for your own medical assessment. If your request describes only pain, fatigue, or another symptom, ask whether further diagnostic work is needed before any treatment can be considered.

The clinic may lack the necessary scope or support

In Japan, a service provided under the Act on the Safety of Regenerative Medicine follows a different regulatory route from marketing approval of a regenerative medical product. The Act classifies technologies into Classes I, II, and III, and requires advance submission of a provision plan with the relevant certified committee’s opinion. A filed provision plan is not product marketing approval or proof of efficacy En. Product approvals and their review reports are listed separately by PMDA 0004.

Ask whether the refusal relates to any of these practical limits:

  • Your condition, proposed cell source, or administration method is outside the clinic’s service scope.
  • The required specialist, cell processing facility, or emergency support is unavailable.
  • The clinic cannot complete the required explanation and consent process.
  • You cannot attend the observation or follow-up appointments required by the proposed plan.

The Act addresses explanation and consent in Article 14, and suspected treatment-related illness and infection reporting in Articles 17 and 18 En. Ask how those requirements apply to the service being discussed, rather than treating a plan number as a safety guarantee.

If you intend to fly home after treatment, ask how long you must remain nearby, who will handle problems after you leave, and whether local aftercare is required. Do not assume there is one safe departure interval for every procedure.

The expected benefit may not justify treatment

A clinic may be unable to support the result you are requesting. Ask what evidence applies to your exact diagnosis, disease stage, cell product, and administration route. Human study results need context: the number of participants, comparison group, measured outcomes, follow-up duration, and reported adverse events. A study registration alone does not establish effectiveness.

FDA specifically warns that a ClinicalTrials.gov listing or a firm’s FDA registration does not mean a product is legally marketed Important patient and consumer information about regenerative medicine therapies. Its U.S. consumer warning is not a substitute for checking the applicable pathway in Japan. Ask which route applies to the actual offer using the registration and compliance overview as background.

If the clinic recommends established care first, ask which option it means and why. Do not delay your existing treatment while looking for a clinic that will promise a cure. FDA’s safety warning includes the risk that an unapproved therapy will not work as anticipated when approved treatments are available Important patient and consumer information about regenerative medicine therapies.

What to do after a decline

Ask for the reason in writing and clarify what kind of decision you have received. Clinics may use “declined” and “deferred” differently; neither word, on its own, tells you whether reassessment is possible.

What the clinic means What to ask next What not to assume
More information is needed Which report, test, or specialist assessment is missing, and who will review it? That an incomplete review is a final medical rejection.
Treatment is on hold for a medical or practical concern What needs to change, and when would reassessment be appropriate? That resolving one issue guarantees acceptance.
This treatment is outside the clinic’s scope or is unsuitable Is another established treatment or a specialist referral appropriate? That another clinic’s willingness to accept you proves safety or benefit.

A specific request you can send

“Please explain the main reason treatment was declined. Is the decision based on missing information, a medical concern, the treatment’s suitability, or your clinic’s scope? What would need to change before you could reconsider, and which specialist or established treatment should I discuss with my doctor meanwhile?”

For a records-related refusal, put the decline letter, relevant test reports, medicine list, and specialist letters together. Label each report with its date and ask whether the reviewer needs the original imaging files as well as the written report. This is a preparation checklist, not a promise of a faster answer or eventual approval.

When a second opinion helps

A second opinion can help clarify a disputed diagnosis, a product mismatch, or a clinic-specific limitation. Share the same records and the original refusal. If the new recommendation differs, ask what evidence or treatment plan accounts for the difference. A second team can reasonably reach a different judgment, but should be able to explain it.

For general questions about the enquiry process, contact patient support. Medical eligibility requires a physician’s assessment. Before sending sensitive records, ask which secure submission method to use.

Contact the Patient Support Team

The bottom line

A clinic can decline treatment because of safety concerns, an unsuitable or unsupported treatment request, missing records, or limits in its service and follow-up arrangements. Get the specific reason, ask what could change the decision, and discuss appropriate alternatives with your treating physician. A reassessment is a review, not a guarantee.

This article provides general information about stem cell and regenerative medicine enquiries. It does not assess your eligibility or replace medical advice from a licensed physician who has reviewed your records.